Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…
Twist Bioscience
(https://twistbioscience.com) 📸 Data Snapshot: June 20, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Twist Bioscience | We lead innovation in DNA synthesis (https://twistbioscience.com)
Title
Twist Bioscience | We lead innovation in DNA synthesis
H2 Genes
H2 Oligo Pools
H2 NGS Target Enrichment Solutions
H2 Variant Libraries
H2 Start Order
H2 GET QUOTE
H2 Unleash the Power of the Platform
H2 Twist at Your Service
H2 Keep Calm and Stay Current
H2 Let’s Start Writing the Future with Twist
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Twist Biopharma Solutions | Twist Bioscience (https://twistbioscience.com/twist-biopharma-solutions/)
Title
Twist Biopharma Solutions | Twist Bioscience
H1 Antibody Discovery Services
H2 Genes
H2 Oligo Pools
H2 NGS Target Enrichment Solutions
H2 Variant Libraries
H2 Start Order
H2 GET QUOTE
H2 Workflows and Corresponding Timelines
H2 Our Services
H2 Our Numbers Speak for Themselves
H2 Companies We've Partnered With
H2 What Scientists Have to Say
H2 Explore More
H2 Get in Touch With Us
H3 A New Era in Antibody Discovery
H6 Antibody Discovery
H6 Antibody Services
H6 Best-in-class Technologies
H6 License Existing Twist-Discovered Abs
H6 Twist Biopharma Brochure
H6 Single Domain Antibody Libraries (VHH)
H6 Accelerate Your Discovery Efforts with Twist Antibody Libraries
H6 Writing the Future of Biologics to Discover and Optimize Antibodies
NAV_HEADER_REPEATED_BODY Synthetic Viral Controls (https://twistbioscience.com/products/ngs/synthetic-viral-controls/)
Title
Synthetic Viral Controls
H1 Synthetic Viral Controls
H2 Genes
H2 Oligo Pools
H2 NGS Target Enrichment Solutions
H2 Variant Libraries
H2 Start Order
H2 GET QUOTE
H2 Quote Request
H2 Mpox Virus Controls
H2 Related Resources
H2 The use of positive controls in quality control
H2 Best practices for using Assay Ready and Encapsulated Controls
H2 Available respiratory virus controls
H2 Blog
H2 Product Sheet
H2 Application Note
H2 Technical Note
H2 Technical Document
H3 Blogs
H3 Publications
H3 Protocols
H3 Product List
NAV_HEADER_REPEATED AI Drug Discovery (https://twistbioscience.com/applications/ai-drug-discovery/)
Title
AI Drug Discovery
H1 Great models demand great data
H2 Genes
H2 Oligo Pools
H2 NGS Target Enrichment Solutions
H2 Variant Libraries
H2 Start Order
H2 GET QUOTE
H2 High-fidelity data.15-day velocity.
H2 Let your team focus on AI,
Twist handles the wet lab.
H2 Power your AI-guided
drug discovery
H2 10+ characterization assays,
all in one workflow
H2 Binding assessment assays
H2 Developability assays
H2 Cell-based functional assays
H2 Let's talk about your pipeline
H3 Rapid feedback for better models
H3 Full antibody generation at AI scale
H3 Trusted data for confident decisions
H3 Have custom or complex project needs?
H3 Binding kinetics: affinity ranking (SPR)
H3 On-cell binding confirmation: flow cytometry
H3 Biophysical characterization: epitope binning (SPR)
H3 Developability assessment: aggregation
H3 Developability assessment: size distribution
H3 Thermal stability
H3 Off-target binding: BVP-ELISA or AC-SINS
H3 Hydrophobicity
H3 Functional characterization
H5 For Research Use Only.
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://twistbioscience.com) Twist Bioscience | We lead innovation in DNA synthesis
[IMG: DRUG DISCOVERY] [IMG: CANCER RESEARCH] [IMG: HUMAN GENETICS] [IMG: AGBIO AND ANIMAL HEALTH] [IMG: INFECTIOUS DISEASES] WRITING THE FUTURE OF DRUG DISCOVERY CANCER RESEARCH HUMAN GENETICS AGBIO AND ANIMAL HEALTH INFECTIOUS DISEASES DRUG DISCOVERY CANCER RESEARCH HUMAN GENETICS AGBIO AND ANIMAL HEALTH INFECTIOUS DISEASES DRUG DISCOVERY CANCER RESEARCH HUMAN GENETICS AGBIO AND ANIMAL HEALTH INFECTIOUS DISEASES DRUG DISCOVERY CANCER RESEARCH HUMAN GENETICS AGBIO AND ANIMAL HEALTH INFECTIOUS DISEASES DRUG DISCOVERY CANCER RESEARCH HUMAN GENETICS AGBIO AND ANIMAL HEALTH INFECTIOUS DISEASES Our DNA-based tools are enabling researchers across a variety of scientific disciplines to achieve groundbreaking discoveries. We continue to drive biological innovations aimed at making the world safer, healthier and more sustainable. EXPLORE OUR PRODUCTS Special offer for new customers: 30% discount on initial Multiplexed Gene Fragments Order. LEARN MORE [IMG: MGF] Our Products [IMG: Genes] Genes DNA Your Way: think bigger, expand your scope, and accelerate discovery [IMG: Libraries] Libraries Identify more hits and streamline screening with precise Variant Libraries [IMG: NGS] NGS Raise confidence in variant detection with superior target enrichment solutions [IMG: Oligo Pools] Oligo Pools Precision, uniformity, and flexibility for results you can trust [IMG: Synthetic Controls] Synthetic Controls Synthetic RNA and DNA standards for assay development [IMG: Antibody Services] Antibody Services Robust solutions for Antibody Discovery and Development [IMG: Twist silicon platform] [H2] [H2] Unleash the Power of the Platform Twist Bioscience developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a high-throughput silicon platform that allows us to miniaturize the chemistry necessary for DNA synthesis. This translates into time and cost savings for our customers across their workflows. Researchers can access quality tools for more accurate NGS, highly customizable Gene Synthesis at scales that fit any workflow, more accurate genomic screens that require fewer resources, and libraries with optimized discovery power as every variant is directly synthesized. LEARN MORE [IMG: Twist Scientific Experts] [H2] [H2] Twist at Your Service Twist’s Technical Support team is available to help you tackle your biggest research challenges. Hear what our customers have to say: “We are very pleased with the quality of both the service provided by Twist and their customer support. Twist has always replied promptly and worked hard to solve any of our issues as quickly as possible. Furthermore, their Science team has always shown availability to help customize their services to our needs. I would definitely recommend Twist’s services to others." Lead Strain Engineer Stealth Mode Biotechnology Company LEARN MORE Powering Today’s Research [IMG: A CRE.AI.TIVE application of AI: Engineering a more resilient global food supply] A CRE.AI.TIVE application of AI: Engineering a more resilient global food supply Genes Using oligo pools, Phytoform Labs screened thousands of AI-designed DNA sequences—streamlining trait engineering, accelerating crop improvement, and optimizing R&D resources [IMG: Deciphering Feline Mutations Through Whole Exome Sequencing with Twist] Deciphering Feline Mutations Through Whole Exome Sequencing with Twist NGS [IMG: Exploring Redwood Genomic Complexity Through Custom NGS Panels] Exploring Redwood Genomic Complexity Through Custom NGS Panels NGS [H2] Keep Calm and Stay Current ALL BLOGS Press & Accolades [IMG: We’re proud to be a Great Place to Work-Certified™ company!] USA - We’re proud to be a Great Place to Work-Certified™ company! Couldn’t be prouder – we put our people first View article [IMG: #6 Most Innovative Biotech Companies of 2021] #6 Most Innovative Biotech Companies of 2021 Our innovations help fight COVID (and beyond) View article [IMG: On the list of Fast 500 Technology Companies of 2020 & 2021] On the list of Fast 500 Technology Companies of 2020 & 2021 We're proud of our products + customer service View article [IMG: career image] [H2] Let’s Start Writing the Future with Twist Open Positions
4790 chars
SUB-PAGE (https://twistbioscience.com/twist-biopharma-solutions/) Twist Biopharma Solutions | Twist Bioscience
[IMG: Banner] [H2] [H1] Antibody Discovery Services Where in vivo meets in vitro for end-to-end drug discovery solutions SPEAK TO A SCIENTIST [H3] A New Era in Antibody Discovery Modern therapeutic targets are getting more challenging and traditional, single modality platforms are no longer sufficient on their own. Twist Bioscience Solutions is the union of two of the industry’s best antibody discovery service providers who together provide our partners with the “discovery trifecta” – in vivo, in vitro and in silico antibody discovery all under one roof. Twist Biopharma Solutions' (TBS) one of a kind discovery services offer our partners improved diversity, improved screening, ultra fast lead selection and engineering, which can mean a faster path in the race to the clinic. [H2] Workflows and Corresponding Timelines We offer three workflow options to our partners to ensure their needs are met within their desired timelines. Choose which workflow best fits your needs, or work with a scientist to determine a path. [H2] Our Services We offer a full suite of capabilities to best serve our partners’ needs. Find out more about our service offerings by clicking below. [IMG: Antibody Discovery] [H6] Antibody Discovery Industry-leading discovery solutions [IMG: Antibody Services] [H6] Antibody Services A la carte discovery, screening and characterization services [IMG: Best-in-class Technologies] [H6] Best-in-class Technologies Capabilities fueled by market-leading technologies [IMG: License Existing Twist-Discovered Abs] [H6] License Existing Twist-Discovered Abs High-value targets made druggable with Twist-discovered antibodies Dynamic Counter [H2] Our Numbers Speak for Themselves 0 Successful mAb discovery campaigns completed in industry-leading timelines 0 Partnerships spanning all therapeutic areas 0 mAb candidates discovered by Twist Biopharma Solutions in clinical trials 0 Industry’s best platforms spanning three different technologies to ensure all shots on goal Horizontal Carousel Example [H2] Companies We've Partnered With [IMG: ONO.] [IMG: Bayer] [IMG: logo-2.] [IMG: logo-3] [IMG: logo-4] [IMG: logo-5] [IMG: logo-6] [IMG: logo-7] [IMG: logo-8] [H2] What Scientists Have to Say “ Twist is the only synthetic DNA provider who can deliver the quantity and quality of DNA we need for our projects rapidly. We are working with them not only as a vendor for synthetic genes and antibodies, but have expanded our relationship to leverage the Twist Biopharma capabilities, which we believe complement our antibody discovery efforts.” ROBERT CARNAHAN, PHD Associate Director of the Vanderbilt Vaccine Center “ Our platform rapidly generates and validates new targets for treating challenging cancers. Working with Abveris will enable us to quickly identify and select highly specific antibodies for those targets, so that we can take the best antibody forward to address the needs of particular patient populations.” JEFF GOLDBERG, CEO Immunitas Therapeutics What Scientists Have to Say Twist is the only synthetic DNA provider who can deliver the quantity and quality of DNA we need for our projects rapidly. We are working with them not only as a vendor for synthetic genes and antibodies, but have expanded our relationship to leverage the Twist Biopharma capabilities, which we believe complement our antibody discovery efforts.” ROBERT CARNAHAN, PHD Associate Director of the Vanderbilt Vaccine Center Our platform rapidly generates and validates new targets for treating challenging cancers. Working with Abveris will enable us to quickly identify and select highly specific antibodies for those targets, so that we can take the best antibody forward to address the needs of particular patient populations.” JEFF GOLDBERG, CEO Immunitas Therapeutics Previous Next Pause Play Container 1 Container 2 [H2] Explore More All Resources View All [H6] Twist Biopharma Brochure [IMG: Icon] Brochure Biopharma Twist Biopharma is committed to helping you realize the potential of your biggest biologic development programs. Wherever you are in the development pipeline, we have a solution that will elevate you to the next level of discovery. Learn More [H6] Single Domain Antibody Libraries (VHH) [IMG: Icon] Product Sheet Biopharma Create and explore large, diverse naïve VHH antibody libraries for therapeutic development Learn More [H6] Accelerate Your Discovery Efforts with Twist Antibody Libraries [IMG: Icon] Product Sheet Biopharma Discover how the synthetic advantage can streamline your discovery efforts with Twist Antibody Libraries. Twist Bioscience capitalizes on its massively parallel DNA synthesis platform to generate custom antibody libraries that meet your needs. Complementing this service is the Library of Libraries, a collection of synthetic antibody libraries offered off-the-shelf by Twist Biopharma, a division of Twist Bioscience. Every ready-to-use library offers unique, drug-like antibodies and comes with advanced design support from Twist Biopharma. Compared to those from immunized sources, Twist Antibody Libraries are more diverse, cost-effective, and faster to obtain, making antibody discovery easier than ever before. Learn More [H6] Writing the Future of Biologics to Discover and Optimize Antibodies [IMG: Icon] Webinar Biopharma Monoclonal antibodies have become the preferred therapeutic modality for cancer, infectious diseases, inflammatory and autoimmune disorders, and other conditions. Twist Bioscience is on a mission to support this work, offering a Library of Libraries containing multiple pre-constructed and validated libraries against many high-value targets with which scientists can build a comprehensive and robust antibody discovery platform. Here we introduce the latest addition to our Library of Libraries: the Hyperimmune Library. Join our webinar with Steven Thomas from Twist Biopharma, a division of Twist Bioscience, to: Review recent work from Twist Biopharma using the Library of Libraries against human ACE2 and the SARS-CoV-2 spike protein to find potently neutralizing candidate antibodies against the SARS-CoV-2 strain of coronavirus in under 4 weeks. Learn More More Resources [H2] Get in Touch With Us Antibody enthusiasts are standing by and would love to hear more about your discovery needs. Challenging targets welcome!
7063 chars
SUB-PAGE (https://twistbioscience.com/products/ngs/synthetic-viral-controls/) Synthetic Viral Controls
× [H2] Quote Request Please fill out the form below to notify your sales rep × DISMISS [H2] [H1] Synthetic Viral Controls Reproducible. Accurate. Safe. MPOX VIRUS CONTROLS SARS-COV-2 CONTROLS RESPIRATORY VIRUS CONTROLS RESOURCES BUY NOW [H2] Mpox Virus Controls Twist’s Synthetic human Mpox Virus (hMPXV) Controls are based on sequences from either the Congo Basin (CB) or West African (WA) clades of hMPXV, formerly known as Monkeypox, and provide coverage of ≥80% of the viral genome. As a result, these controls support the design of custom assays targeting regions of the genome relevant to orthopoxvirus research and can be used for both amplicon and capture-based detection methods. Twist’s hMPXV controls have been validated and are compatible with CDC-recommended real-time PCR testing procedures for Mpox detection. Control 1 and Control 2 are composed of 154 and 151 overlapping 1.8kb fragments, respectively, which tile the genome at an interval of 900bp. Each control is present at copies and provided at a concentration of approximately 100,000 copies/μL. The figure on the right shows the taxonomic relationships among the WA and CB clades of hMPXV and other orthopoxviruses. Please contact your local sales representative for more information. Note: The Twist Synthetic human Mpox Virus (hMPXV) Controls are not ISO-13485 certified [IMG: mpox] × Virus name Genbank IDs, virus type, and lengths Virus name Genbank IDs, virus type, and length for each virus included in the Twist Respiratory Virus Controls [IMG: table] × [H2] Related Resources [H3] Blogs Tracking Nigeria’s Monkeypox (Mpox) Outbreak with Next Generation Sequencing Synthetic DNA’s Critical Role in Infectious Disease Research [H3] Publications Pan Viral Sequencing Panel Genomic characterisation of human monkeypox virus in Nigeria Clade I Mpox virus genomic diversity in the Democratic Republic of the Congo, 2018 - 2024: Predominance of Zoonotic Transmission Wastewater sequencing reveals community and variant dynamics of the collective human virome Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo Intra- and interhost genomic diversity of monkeypox virus Use of Mpox Multiplex Serology in the Identification of Cases and Outbreak Investigations in the Democratic Republic of the Congo (DRC) Synthetic Controls Clade-Specific MPXV PCR Assays Extraction-free LAMP assays for generic detection of Old World Orthopoxviruses and specific detection of Mpox virus [H3] Protocols CDC Mpox Protocols [H3] Product List Twist Synthetic Infectious Disease Controls Product List BUY NOW [H2] The use of positive controls in quality control Twist has created synthetic RNA controls for several viral genomes. These variants were selected to cover a wide range of sequence diversity. Each control consists of six non-overlapping 5 kb fragments generated from Twist Gene Fragments then transcribed into ssRNA. These controls provide coverage of greater than 99.9% of the bases of the SARS-CoV-2 viral genome. The majority of the controls are provided in the standard format which consist of 100 μL at a concentration of approximately one million copies per microliter. Twist also offers certain controls in Assay Ready and Encapsulated Formats that are supplied as a desiccated pellet. The Assay Ready Controls are supplied at approximately two million copies per tube. The Encapsulated Controls are supplied at approximately 50,000 copies per tube. The Twist Assay Ready Synthetic SARS-CoV-2 RNA Control was developed in partnership with the US CDC and integrated into the CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay, which tests for influenza A, B and SARS-CoV-2 simultaneously. The Twist Assay Ready Synthetic SARS-CoV-2 RNA Control is now available for customers outside the CDC. Twist Bioscience Encapsulated Control products offer a unique storage and delivery method for Twist’s established Synthetic SARS-CoV-2 RNA controls. Just as protein encapsulation of viruses offers more stable molecular storage, Twist’s Encapsulated Control products leverage a novel method to seal a metal capsule around a desiccated pellet to enhance stability of the RNA controls. Due to the enhanced stability, they can be shipped and stored at room temperature, reducing cost and improving accessibility globally. The Encapsulated Controls are sold in a rack of 16 or 96 tubes, are single use, and have a 5-year shelf life from the date of manufacture. [H2] Best practices for using Assay Ready and Encapsulated Controls For the Storage and use of Assay Ready or Encapsulated SARS-CoV-2 Controls please review the Following documents: Twist Assay Ready Synthetic Controls Storage and Use DocumentTwist Sars-CoV-2 Encapsulated RNA Control Storage and Handling Guide This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, along with the identification and differentiation of SARS-CoV-2 PANGO lineages and the identification of specific SARS-CoV-2 genomic mutations, not for any other viruses or pathogens; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. [IMG: NGS SARS-CoV-2 Synthetic RNA Controls Genome] × PART # CONTROL GenBank/GISAID ID GISAID NAME 102019 Control 1 MT007544.1 Australia/VIC01/2020 102024 Control 2 MN908947.3 Wuhan-Hu-1 103925 Assay Ready Control 2 MN908947.3 Wuhan-Hu-1 104422 Encapsulated Control 2 (16) MN908947.3 Wuhan-Hu-1 104426 Encapsulated Control 2 (96) MN908947.3 Wuhan-Hu-1 102860 Control 3 LC528232.1 Japan/Hu_DP_Kng_19-020/2020 102862 Control 4 MT106054.1 USA/TX1/2020 102917 Control 5 MT188340 USA/MN2-MDH2/2020 102918 Control 6 MT118835 USA/CA9/2020 103087 Control 7 EPI_ISL_418227 France/HF2393/2020 103511 Control 8 MT066176 Taiwan/NTU02/2020 103512 Control 9 MT152824 USA/WA2/2020 103513 Control 10 EPI_ISL_414648 USA/CA-PC101P/2020 103514 Control 11 EPI_ISL_417739 Iceland/5/2020 103515 Control 12 EPI_ISL_420244 England/SHEF-C05B2/2020 103533 Control 13 EPI_ISL_421184 Belgium/ULG-10004/2020 103907 Control 14 Alpha EPI_ISL_710528 England/205041766/2020 103926 Assay Ready Control 14 Alpha (B.1.1.7) EPI_ISL_710528 England/205041766/2020 103909 Control 15 Alpha EPI_ISL_601443 England/MILK-9E05B3/2020 103927 Assay Ready Control 15 Alpha (B.1.1.7) EPI_ISL_601443 England/MILK-9E05B3/2020 104043 Control 16 Beta (B.1.351) EPI_ISL_678597 South Africa/KRISP-EC-K005299/2020 104044 Control 17 Gamma (P.1) EPI_ISL_792683 Japan (Brazil) /IC-0564/2021 104338 Control 18 Kappa (B.1.617.1) EPI_ISL_1662307 India/CT-ILSGS00361/2021 104529 Control 19 Iota (B.1.526) EPI_ISL_1300881 USA/NY-MSHSPSP-PV24650/2020 104530 Control 20 (B.1.427) EPI_ISL_730092 USA/CA-ALSR-4704/2020 104531 Control 21 Epsilon (B.1.429) EPI_ISL_672365 USA/CA-CZB-12943/2020 104532 Control 22 (B1.1.519) EPI_ISL_933685 Mexico/CMX-InDRE_208/2021 104533 Control 23 Delta (B.1.617.2) EPI_ISL_1544014 India/MH-NCCS-P1162000182735/2021 104534 Control 24 (B.1.617.3) EPI_ISL_1939891 India/MH-SEQ-221_S66_R1_001/2021 104538 Control 28 Delta (AY.1) EPI_ISL_2695467 Portugal/PT9543/2021 104423 Encapsulated Control 28 (16) Delta (AY.1) EPI_ISL_2695467 Portugal/PT9543/2021 104427 Encapsulated Control 28 (96) Delta (AY.1) EPI_ISL_2695467 Portugal/PT9543/2021 104539 Control 29 Delta (AY.2) EPI_ISL_2693246 USA/WA-CDC-UW21061750277/2021 105204 Control 48 (B.1.1.529/BA.1) EPI_ISL_6841980 Hong Kong/HKU-211129-001/2021 104424 Encapsulated Control 48 (16) (B.1.1.529/BA.1) EPI_ISL_6841980 Hong Kong/HKU-211129-001/2021 104428 Encapsulated Control 48 (96) (B.1.1.529/BA.1) EPI_ISL_6841980 Hong Kong/HKU-211129-001/2021 105345 Control 50 (B.1.1.529+BA.2) EPI_ISL_7190366 Australia/QLD2568/2021 105346 Control 51 (B.1.1.529+BA.2) EPI_ISL_7718520 England/MILK-2DF642C/2021 105865 Control 62 (B.2.12.1) EPI_ISL_12248637.1 Denmark/DCGC-493190/2022 105857 Control 63 (B.2.12.1) EPI_ISL_12303256.1 USA/NY-CDC-LC0579415/2022 106196 Control 64 (BA.5) EPI_ISL_12516495 hCoV-19/England/LSPA-3DC1269/2022 106197 Control 65 (BA.5) EPI_ISL_12620611 hCoV-19/USA/TN-ASC-210769476/2022 106198 Control 66 (BA.4) EPI_ISL_12454576 hCoV-19/USA/TX-HMH-M-96682/2022 106199 Control 67 (BA.4) EPI_ISL_12605687 hCoV-19/USA/CA-CDC-QDX36065390/202 106929 Control 70 EPI_ISL_14829147 hCoV-19/USA/MI-CDC-QDX40579621/2022 106930 Control 71 EPI_ISL_15381979 hCoV-19/Australia/SA464919/2022 BUY NOW [H2] Available respiratory virus controls The Twist Synthetic Respiratory Virus Controls cover a broad range of RNA and DNA viruses relevant to respiratory disease research. These controls are aligned with the content of the Twist Respiratory Virus Research Panel (PN 103067) and are suitable for use with Twist Fixed Panel NGS workflows or for use with RT-PCR or qPCR experiments of your own design. This figure shows a select taxonomic tree of viruses covered by the Twist Respiratory Virus Controls. The table shows GenBank IDs, virus type and length for each control. Additional viral controls may be available for custom synthesis. Please contact your local sales representative for more details. [IMG: NGS Respiratory Viral Controls Taxonomic Tree] × Virus name Genbank IDs, virus type, and lengths Virus name Genbank IDs, virus type, and length for each virus included in the Twist Respiratory Virus Controls. Additional viral controls may be available for custom synthesis. Contact your local sales representative for more details. Part Number Name Accession Virus Type Length (bases) 103001 Twist Synthetic Influenza H1N1 (2009) RNA control NC_026431, NC_026432, NC_026433, NC_026434, NC_026435, NC_026436, NC_026437, NC_026438 ssRNA (- sense) 13158 103002 Temperature: Twist Synthetic Influenza H3N2 RNA control NC_007366, NC_007367, NC_007368, NC_007369, NC_007370, NC_007371, NC_007372, NC_007373 ssRNA (- sense) 14452 103003 Twist Synthetic Influenza B RNA control NC_002204, NC_002205, NC_002206, NC_002207, NC_002208, NC_002209, NC_002210, NC_002211 ssRNA (- sense) 14452 103004 Twist Synthetic Human bocavirus 1 DNA control MG953830.1 ssDNA 5164 103005 Twist Synthetic Human enterovirus 68 RNA control NC_038308.1 ssRNA (+ sense) 7367 103006 Twist Synthetic Human rhinovirus 89 RNA control NC_001617.1 ssRNA (+ sense) 7152 103007 Twist Synthetic Mumps virus RNA control NC_002200.1 ssRNA (- sense) 15384 103008 Twist Synthetic Human parainfluenza virus 1 RNA control NC_003461.1 ssRNA (- sense) 15600 103009 Twist Synthetic Measles virus RNA control NC_001498.1 ssRNA (- sense) 15894 103010 Twist Synthetic Human parainfluenza virus 4 RNA control NC_021928.1 ssRNA (- sense) 17052 103011 Twist Synthetic Human coronavirus 229E RNA control NC_002645.1 ssRNA (+ sense) 27317 103012 Twist Synthetic Human coronavirus NL63 RNA control NC_005831.2 ssRNA (+ sense) 27553 103013 Twist Synthetic Human coronavirus OC43 RNA control NC_006213.1 ssRNA (+ sense) 30741 103730 Twist Respiratory Virus Controls (13 Count) N/A N/A N/A 109012 Twist Synthetic Influenza A (H5N1) RNA Control OR051630.1, OR051629.1 ssRNA (- sense) HA Segment: 1,695, NA Segment: 1,410 [H2] [IMG: icon] Blog Taking Control In H5N1 Bird Flu Research With Synthetic DNA Read more [H2] [IMG: icon] Product Sheet Respiratory Virus Controls Download Twist Synthetic Infectious Disease Controls Product List Download Synthetic SARS-CoV-2 Control Variant Information Download Synthetic SARS-CoV-2 RNA Controls Download [H2] [IMG: icon] Application Note NGS-based Target Capture for SARS-CoV-2 Detection and Characterization Download NGS Target Enrichment of Viral Pathogens using Twist Respiratory Virus Research Panel Download [H2] [IMG: icon] Technical Note Twist Assay Ready Synthetic Controls Download [H2] [IMG: icon] Technical Document Twist SARS-CoV-2 Encapsulated RNA Control Storage and Handling Guide Download
14843 chars
SUB-PAGE (https://twistbioscience.com/applications/ai-drug-discovery/) AI Drug Discovery
Your browser does not support the video tag. For AI/ML teams in drug discovery [H1] Great models demand great data Go from in silico design to physical characterization with Twist. Get sequence-perfect antibodies, a suite of characterization assays, and AI-ready data in as few as 15 days. Talk to an expert Benefit Workflow Assay Suite Contact us [H2] High-fidelity data.15-day velocity. Iterate AI models without wet-lab bottlenecks. Get reproducible binding and developability data in as few as 15 days. 130K+Antibodies assayed 200K+Proteins expressed <15 daysTurnaround time 7M+Data points generated Trusted by 445+ partners How Twist can help [H2] Let your team focus on AI, Twist handles the wet lab. Generate more sequences, move faster, and get model-ready data without taking on the complexity of protein production, assay execution, or data generation. [IMG: hit] [H6] [H3] Rapid feedback for better models Move quickly from predicted sequences to experimental results so your team can train, test, and refine models without wet-lab bottlenecks. [IMG: progression] [H6] [H3] Full antibody generation at AI scale Translate AI-generated designs into physical molecules with a workflow built for throughput, so you can evaluate more candidates faster. [IMG: flexibility] [H6] [H3] Trusted data for confident decisions Generate clean, consistent experimental data for ranking, training, and optimization so your team can move forward with confidence. [H2] Power your AI-guided drug discovery Twist connects sequence generation to documented, model-ready data through an integrated suite of products and services. [IMG: DLBM Diagram] Step 1: Design [H1] Submit sequences Input your sequences from your Gen AI platforms to generate DNA or protein production for wet-lab validation. Order now Step 2: Build [H1] Data generation With high-quality datasets, researchers can train and refine their AI models. Validate those models with Twist Express Antibodies and high-throughput characterization services to generate data from sequences in as few as 15 days. Order now Step 3: Test [H1] Data delivery Twist enables the validation of your AI outputs for thousands of proteins for binding and developability characteristics. Twist offers custom data delivery formats that are benchmarked against clinical antibody controls to ensure high-quality datasets ready for direct use in your AI and machine learning models. Speak to an expert Step 4: Learn [H1] Training & iterations Twist connects your sequences to documented and predictable data sets that you can use to integrate into your models improve your drug discovery and development efforts. Need help designing a program or interpreting your data? Speak to an expert [H3] Have custom or complex project needs? Whether you’re looking for bespoke data configurations or help with MSA contracts, our team is here to help. Talk to an expert Why Twist [H2] 10+ characterization assays, all in one workflow Others can only provide binding confirmation. Twist delivers the full developability picture: every data type your AI model needs to train, rank, and advance leads to clinical validation. [H2] Binding assessment assays [H2] Developability assays [H2] Cell-based functional assays × [H2] Let's talk about your pipeline Tell us where you are in your AI drug discovery journey. Our scientific team will reach out within one business day to discuss how Twist can accelerate your work. [H2] [H5] For Research Use Only. Not for use in diagnostic procedures.
4213 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
80Review mentions (all pages)
0External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 1 | 0 |
| /twist-biopharma-solutions/ | 45 | 0 |
| /products/ngs/synthetic-viral-controls/ | 20 | 0 |
| /applications/ai-drug-discovery/ | 14 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage — no schema detected (entity gap)
/twist-biopharma-solutions/ — no schema detected (entity gap)
/products/ngs/synthetic-viral-controls/ — no schema detected (entity gap)
/applications/ai-drug-discovery/ — no schema detected (entity gap)
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Information Density
0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence
0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof
0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint
0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority
0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score
0 / 100
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Information Density
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Semantic Alignment
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Trust & Proof
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Commodity Fingerprint
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Identity & Authority
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS
Based on 784 businesses audited.
BS Detector
Medical Devices, Pharma & Biotech BS: Twist Bioscience (twistbioscience.com)
https://twistbioscience.com
📍 Industry: Medical Devices, Pharma & Biotech
33
BS / 100
Twist Bioscience is a high-substance technical entity wrapped in a slightly thin marketing shell. While the homepage uses standard corporate biotech fluff, the underlying product data is forensically detailed and provides the ‘discovery trifecta’ it claims.
Info Density
Power-words vs. Substance ratio.
7
23% BS
Semantic Coherence
Homepage promise vs. Sub-page reality.
3
15% BS
Trust & Proof
Verifiable evidence vs. Trust Theatre.
0
0% BS
Commodity Fingerprint
Detection of industry clichés/templates.
6
40% BS
Identity & Authority
Expert verifiability & Schema depth.
8
53% BS
Implement Organization and Product JSON-LD schema to bridge the authority gap. Replace the generic counters on the Biopharma page (currently showing 0) with actual partnership and clinical trial metrics. Add direct citations or outbound links to the peer-reviewed publications mentioned on the Viral Controls page to move from trust theatre to verified proof. Fill the missing meta description on the homepage to align technical SEO with claims of technical excellence.
The content perfectly aligns with the Pharma and Biotech sector, specifically focusing on synthetic biology, DNA synthesis, and antibody discovery. Technical references to GenBank IDs, ssRNA, and NGS Target Enrichment confirm a high degree of industry-specific accuracy.
“The score is primarily driven by missing structured data (Identity) and the presence of trust theatre (unlinked reviews), though it is significantly lowered by the high density of technical specifications and unique platform positioning.”
Verified Analysis Date: June 20, 2026
© 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution
This training module utilizes a snapshot of public data from Twist Bioscience, captured on June 20, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Twist Bioscience: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://twistbioscience.com to view the most current version of its content and learn from the source what this company is about and what it offers.